NCT00027599View on ClinicalTrials.gov

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

July 31, 2007

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

bevacizumab

BIOLOGICAL

prostatic acid phosphatase-sargramostim fusion protein

BIOLOGICAL

sipuleucel-T

BIOLOGICAL

therapeutic autologous dendritic cells

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Trial Locations (1)

94115

UCSF Comprehensive Cancer Center, San Francisco

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00027599 - APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter